A case of immune reconstitution syndrome: adult-onset Still's disease in a patient with HIV infection.

1 Minden K, Niewerth M, Listing J et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002;46:2392–401. 2 Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. J Am Med Assoc 2005;294:1671–84. 3 Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr 2006;95(Suppl.):38–41. 4 Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793–806. 5 Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572–81. 6 hmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset Still’s disease with rituximab. Ann Rheum Dis 2006;65: 1117–18. 7 Kuek A, Hazleman BL, Gaston JH, Ostor AJ. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology 2006; 45:1448–9. 8 Murray KJ, Grom AA, Thompson SD, Lieuwen D, Passo MH, Glass DN. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 1998;25:1388–98. 9 Wouters CH, Ceuppens JL, Stevens EA. Different circulating lymphocyte profiles in patients with different subtypes of juvenile idiopathic arthritis. Clin Exp Rheumatol 2002;20:239–48.